Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
Alan G. Ramsay, … , John C. Byrd, John G. Gribben
Alan G. Ramsay, … , John C. Byrd, John G. Gribben
Published June 12, 2008
Citation Information: J Clin Invest. 2008;118(7):2427-2437. https://doi.org/10.1172/JCI35017.
View: Text | PDF
Research Article Hematology

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

  • Text
  • PDF
Abstract

Cancer is associated with immune deficiency, but the biologic basis of this is poorly defined. Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia (CLL) exhibiting defective immunological synapse formation with APCs. Although this synapse dysfunction was in part a result of the CLL cells having poor APC function, defective actin polymerization was also identified in T cells from patients with CLL. We further demonstrate that, following contact with CLL cells, defects in immune synapse formation were induced in healthy allogeneic T cells. This required direct contact and was inhibited by blocking adhesion molecules on CLL B cells. In T cells from patients with CLL and in T cells from healthy individuals that had been in contact with CLL cells, recruitment of key regulatory proteins to the immune synapse was inhibited. Treatment of autologous T cells and CLL cells with the immunomodulating drug lenalidomide resulted in improved synapse formation. These results define what we believe to be a novel immune dysfunction in T cells from patients with CLL that has implications for both autologous and allogeneic immunotherapy approaches and identifies repair of immune synapse defects as an essential step in improving cancer immunotherapy approaches.

Authors

Alan G. Ramsay, Amy J. Johnson, Abigail M. Lee, Güllü Gorgün, Rifca Le Dieu, William Blum, John C. Byrd, John G. Gribben

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2005 Total
Citations: 10 17 12 24 35 17 18 16 22 21 22 18 22 16 15 11 14 1 1 312
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (312)

Title and authors Publication Year
Tumor cells escape immunosurveillance by hampering LFA-1
Upadhyay S, Murugu L, Svensson L
Frontiers in Immunology 2025
Activation-induced thrombospondin-4 works with thrombospondin-1 to build cytotoxic supramolecular attack particles
Cassioli C, Capitani N, Staton CC, Schirra C, Finetti F, Onnis A, Alawar N, Tu SM, Lopresti L, Tatangelo V, Tangredi C, Valvo S, Chang HF, Miccoli A, Compeer EB, Nicholls J, Blazar BR, Marotta G, Wood MJ, Trentin L, Patrussi L, Dustin ML, Becherer U, Baldari CT
Proceedings of the National Academy of Sciences of the United States of America 2025
Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0
Solano F, Criado I, Moreno N, Gomez-Gonzalez C, Lerma-Verdejo A, Teodosio C, Martinez-Moya MD, Luts I, Contreras T, Oliva-Ariza G, Fuentes Herrero B, Serrano-Lozano JM, Almeida J, Orfao A
Cancers 2025
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review
Miklos DB, Riedell PA, Bokun A, Chavez JC, Schuster SJ
Targeted Oncology 2025
Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia
Jacobs CF, Peters FS, Camerini E, Cretenet G, Rietveld J, Schomakers BV, van Weeghel M, Hahn N, Verberk SG, Van den Bossche J, Langeveld M, Kleijwegt F, Eldering E, Zelcer N, Kater AP, Simon-Molas H
Cellular and Molecular Immunology 2025
The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia
Smith AL, Ridout A, Skupa SA, Martinez-Rico R, Drengler EM, Mohamed E, D\u2019Angelo CR, El-Gamal D
Biomedicines 2025
Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia
Gamal W, Mediavilla-Varela M, Kunta V, Sahakian E, Pinilla-Ibarz J
Frontiers in Cell and Developmental Biology 2025
Polyfunctional CD8(+)CD226(+)RUNX2(hi) effector T cells are diminished in advanced stages of chronic lymphocytic leukemia.
Rezaeifar M, Shahbaz S, Peters AC, Gibson SB, Elahi S
Molecular oncology 2025
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model
Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, Maharaj K, Chavez JC, Powers J, Obermayer A, Shaw TI, Conejo-Garcia JR, Rodriguez PC, Sahakian E, Pinilla-Ibarz J, Kater AP
Blood Advances 2025
A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation
vom Stein AF, Nguyen PH, ten Hacken E
Frontiers in Immunology 2025
BET inhibition reforms the immune microenvironment and alleviates T-cell dysfunction in chronic lymphocytic leukemia
Audrey Smith, Sydney Skupa, Alexandria Eiken, Elizabeth Schmitz, Nolan Williams, Dalia Moore, Christopher D'Angelo, Avyakta Kallam, Matthew Lunning, R Bociek, Julie Vose, Eslam Mohamed, Anna Mahr, Paul Denton, Ben Powell, Gideon Bollag, Dalia El-Gamal
JCI Insight 2024
Maintenance therapy for chronic lymphocytic leukaemia
Lee CH, Wu YY, Huang TC, Lin C, Zou YF, Cheng JC, Chen PH, Jhou HJ, Ho CL
The Cochrane Database of Systematic Reviews 2024
Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing.
Zhou Y, Wang D, Zhou L, Zhou N, Wang Z, Chen J, Pang R, Fu H, Huang Q, Dong F, Cheng H, Zhang H, Tang K, Ma J, Lv J, Cheng T, Fiskesund R, Zhang X, Huang B
Nature Communications 2024
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G, Tatangelo V, Lopresti L, Ulivieri C, Capitani N, Tangredi C, Finetti F, Marotta G, Frezzato F, Visentin A, Ciofini S, Gozzetti A, Bocchia M, Calzada-Fraile D, Martin Cofreces NB, Trentin L, Patrussi L, Baldari CT
Cell Death and Disease 2024
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.
Amatya C, Weissler KA, Fellowes V, Lam N, Cutmore LC, Natrakul DA, Highfill SL, Kochenderfer JN
2024
p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L, Capitani N, Tatangelo V, Tangredi C, Boncompagni G, Frezzato F, Visentin A, Marotta G, Ciofini S, Gozzetti A, Bocchia M, Trentin L, Baldari CT, Patrussi L
Frontiers in Cell and Developmental Biology 2024
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them
Borogovac A, Siddiqi T
2024
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia
Nunes J, Tafesse R, Mao C, Purcell M, Mo X, Zhang L, Long M, Cyr MG, Rader C, Muthusamy N
Nature Communications 2024
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E
International journal of molecular sciences 2024
Vaccinations in Patient with Chronic Lymphocytic Leukemia
Francis ER, Vu J, Perez CO, Sun C
Seminars in Hematology 2024
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, Röthemeier C, Neuber B, Hückelhoven-Krauss A, Brüggemann M, Bernhard H, Kobbe G, Lindemann A, Rummel M, Michels B, Korell F, Ho AD, Müller-Tidow C, Schmitt M
Leukemia 2024
T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells
van Bruggen JA, Peters FS, Mes M, Rietveld JM, Cerretani E, Cretenet G, van Kampen R, Jongejan A, Moerland PD, Melenhorst JJ, van der Windt GJ, Eldering E, Kater AP
Blood Advances 2024
Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity.
Shen J, Senes F, Wen X, Monti P, Lin S, Pinna C, Murtas A, Podda L, Muntone G, Tidore G, Arru C, Sanna L, Contini S, Virdis P, Sechi LA, Fozza C
Immunologic research 2024
Assaying and classifying T cell function by cell morphology
Wang X, Fernandes SM, Brown JR, Kam LC
BioMedInformatics 2024
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
Yan Y, Tu Y, Cheng Q, Zhang J, Wang E, Deng Z, Yu Y, Wang L, Liu R, Chu L, Kang L, Liu J, Li X
Journal of Translational Medicine 2024
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
Heitmann JS, Jung S, Wacker M, Maringer Y, Nelde A, Bauer J, Denk M, Hoenisch-Gravel N, Richter M, Oezbek MT, Dubbelaar ML, Bilich T, Pumptow M, Martus P, Illerhaus G, Denzlinger C, Steinbach F, Aulitzky WE, Müller MR, Dörfel D, Rammensee H, Salih HR, Walz JS
Frontiers in Immunology 2024
Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers
Kater AP, Siddiqi T
Hematology: the American Society of Hematology Education Program 2024
Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors
Martens AW, Kavazović I, Krapić M, Pack SM, Arens R, Jongejan A, Moerland PD, Eldering E, van der Windt GJ, Wensveen FM, Peters FS, Kater AP
Leukemia 2023
Emerging Therapies in CLL in the Era of Precision Medicine.
Iyer P, Wang L
Cancers 2023
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov AV
Leukemia 2023
Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia
Oder B, Chatzidimitriou A, Langerak AW, Rosenquist R, Österholm C
Frontiers in Oncology 2023
Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities
Brunell AE, Lahesmaa R, Autio A, Thotakura AK
Frontiers in immunology 2023
Pericyte-Glioblastoma Cell Interaction: A Key Target to Prevent Glioblastoma Progression.
Pombero A, Garcia-Lopez R, Martínez S
Cells 2023
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M
Blood Advances 2023
Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
Maggioni G, Fedrigo M, Visentin A, Carturan E, Ruocco V, Trentin L, Alaibac M, Angelini A
Current Oncology 2023
T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
Lam V, Roleder C, Liu T, Bruss N, Best S, Wang X, Phillips T, Shouse G, Berger AJ, Alinari L, Wang L, Siddiqi T, Pennock ND, Danilov AV
Molecular cancer therapeutics 2023
Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies
Shetab Boushehri S, Essig K, Chlis NK, Herter S, Bacac M, Theis FJ, Glasmacher E, Marr C, Schmich F
Nature Communications 2023
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
Vitale C, Griggio V, Perutelli F, Coscia M
HemaSphere 2023
Chronic Lymphocytic Leukemia: Disease Biology
Koehrer S, Burger JA
Acta haematologica 2023
EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
Armin Rehm, Anthea Wirges, Dana Hoser, Cornelius Fischer, Stefanie Herda, Kerstin Gerlach, Sascha Sauer, Gerald Willimsky, Uta Höpken
JCI Insight 2022
Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners
Byeongho Jung, Gerardo Ferrer, Pui Yan Chiu, Rukhsana Aslam, Anita Ng, Florencia Palacios, Michael Wysota, Martina Cardillo, Jonathan E. Kolitz, Steven L. Allen, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi, Barbara Sherry
JCI Insight 2022
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib
N Purroy, Y Tong, C Lemvigh, N Cieri, S Li, E Parry, W Zhang, L Rassenti, T Kipps, S Slager, N Kay, C Lesnick, T Shanafelt, P Ghia, L Scarfò, K Livak, P Kharchenko, D Neuberg, L Olsen, J Fan, S Gohil, C Wu
Blood 2022
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
C Funk, S Wang, K Chen, A Waller, A Sharma, C Edgar, V Gupta, S Chandrakasan, J Zoine, A Fedanov, S Raikar, J Koff, C Flowers, S Coma, J Pachter, S Ravindranathan, H Spencer, M Shanmugam, E Waller
Blood 2022
Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia
F Forconi, S Lanham, G Chiodin
Cancers 2022
Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis
Boddicker NJ, Achenbach SJ, Parikh SA, Kleinstern G, Braggio E, Norman AD, Rabe KG, Vachon CM, Lesnick CE, Call TG, Olson JE, Cerhan JR, Kay NE, Hanson CA, Shanafelt TD, Slager SL
Leukemia 2022
Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis
Yu TY, Jhou HJ, Chen PH, Lee CH
Current Oncology 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Fabro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, Palumbo GA, Di Raimondo F
Cancers 2022
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P, Arsenijevic N, Milovanovic M, Arsenijevic A, Milovanovic J
Current Oncology 2022
BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion.
Liu L, Cheng X, Yang H, Lian S, Jiang Y, Liang J, Chen X, Mo S, Shi Y, Zhao S, Li J, Jiang R, Yang DH, Wu Y
Molecular Cancer 2022
Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
van Bruggen JA, van der Windt GJ, Hoogendoorn M, Dubois J, Kater AP, Peters FS
Blood Advances 2022
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J
Frontiers in immunology 2022
CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints
Böttcher M, Böttcher-Loschinski R, Kahlfuss S, Aigner M, Gießl A, Mackensen A, Schlötzer-Schrehardt U, Tüting T, Bruns H, Mougiakakos D
Cells 2022
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
Liu Y, Song Y, Yin Q
Frontiers in immunology 2022
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K
Frontiers in immunology 2022
CAR-T cell combination therapy: the next revolution in cancer treatment.
Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, Al-Gazally ME, Alsaikhan F, Rizaev JA, Mohammad TAM, Tahmasebi S
Cancer Cell International 2022
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)
Cassioli C, Patrussi L, Valitutti S, Baldari CT
International journal of molecular sciences 2022
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C
Journal for ImmunoTherapy of Cancer 2022
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.
Yano M, Byrd JC, Muthusamy N
Cancers 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia
Tettamanti S, Rotiroti MC, Attianese GM, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Rodriguez TV, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating MJ, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MT
Leukemia & Lymphoma 2022
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
Komissarov AA, Kislova M, Molodtsov IA, Petrenko AA, Dmitrieva E, Okuneva M, Peshkova IO, Shakirova NT, Potashnikova DM, Tvorogova AV, Ptushkin VV, Efimov GA, Nikitin EA, Vasilieva E
International journal of molecular sciences 2022
Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
Collins MA, Jung IY, Zhao Z, Apodaca K, Kong W, Lundh S, Fraietta JA, Kater AP, Sun C, Wiestner A, Melenhorst JJ
2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O\u2019Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W
Blood Advances 2022
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Gamal W, Sahakian E, Pinilla-Ibarz J
Blood Advances 2022
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
N Ioannou, PR Hagner, M Stokes, AK Gandhi, B Apollonio, M Fanous, D Papazoglou, LA Sutton, R Rosenquist, RM Amini, H Chiu, A Lopez-Girona, P Janardhanan, FT Awan, J Jones, NE Kay, TD Shanafelt, MS Tallman, K Stamatopoulos, PE Patten, A Vardi, AG Ramsay
Blood 2021
Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response
MD Marco, S Veschi, P Lanuti, A Ramassone, S Pacillo, S Pagotto, F Pepe, JN George-William, C Curcio, M Marchisio, S Miscia, I Innocenti, F Autore, B Vannata, PD Gregorio, MD Gioacchino, S Valentinuzzi, M Iezzi, R Mariani-Costantini, LM Larocca, L Laurenti, A Veronese, R Visone
Cancers 2021
Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential
JH Lee, S Shao, M Kim, SM Fernandes, JR Brown, LC Kam
Frontiers in Cell and Developmental Biology 2021
T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies
V Janelle, JS Delisle
Cancers 2021
Biomechanics of T Cell Dysfunctions in Chronic Diseases
SD Gunasinghe, NG Peres, J Goyette, K Gaus
Frontiers in immunology 2021
T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
E Vlachonikola, K Stamatopoulos, A Chatzidimitriou
Cancers 2021
CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism
M Grioni, A Brevi, E Cattaneo, A Rovida, J Bordini, MT Bertilaccio, M Ponzoni, G Casorati, P Dellabona, P Ghia, M Bellone, A Calcinotto
Blood Advances 2021
Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
C Cuesta-Mateos, JR Brown, F Terrón, C Muñoz-Calleja
Frontiers in immunology 2021
Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia
G Blanco, A Puiggros, B Sherry, L Nonell, X Calvo, E Puigdecanet, PY Chiu, Y Kieso, G Ferrer, F Palacios, M Arnal, M Rodríguez-Rivera, E Gimeno, E Abella, KR Rai, P Abrisqueta, F Bosch, A Calon, A Ferrer, N Chiorazzi, B Espinet
Experimental Hematology 2021
CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia
G DArena, C Vitale, M Coscia, D Lamorte, G Pietrantuono, F Perutelli, F DAuria, T Statuto, L Valvano, A Tomasso, V Griggio, R Jones, G Mansueto, O Villani, S DAgostino, V Viglioglia, VD Feo, F Calapai, C Mannucci, A Sgambato, DG Efremov, L Laurenti
Cancers 2021
Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment
N Capitani, L Patrussi, CT Baldari
International journal of molecular sciences 2021
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
E Vlachonikola, K Stamatopoulos, A Chatzidimitriou
Frontiers in immunology 2021
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
V Mancikova, M Smida
International journal of molecular sciences 2021
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively
C Moreno, C Muñoz, MJ Terol, JÁ Hernández-Rivas, M Villanueva
Journal of Experimental & Clinical Cancer Research 2021
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
N Ioannou, K Jain, AG Ramsay
International journal of molecular sciences 2021
Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
A Allegra, A Tonacci, C Musolino, G Pioggia, S Gangemi
Frontiers in immunology 2021
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL
M Mhibik, EM Gaglione, D Eik, EK Kendall, A Blackburn, K Keyvanfar, MJ Baptista, IE Ahn, C Sun, J Qi, C Rader, A Wiestner
Blood 2021
Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
C Sun, A Wiestner
Hematology/Oncology Clinics of North America 2021
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
J Mihályová, K Hradská, T Jelínek, B Motais, P Celichowski, R Hájek
International journal of molecular sciences 2021
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
I Jiménez, B Tazón-Vega, P Abrisqueta, JC Nieto, S Bobillo, C Palacio-García, J Carabia, R Valdés-Mas, M Munuera, L Puigdefàbregas, G Parra, A Esteve-Codina, C Franco-Jarava, G Iacoboni, MJ Terol, JA García-Marco, M Crespo, F Bosch
Biomarker Research 2021
The Key Role of NAD+ in Anti-Tumor Immune Response: An Update
F Morandi, AL Horenstein, F Malavasi
Frontiers in immunology 2021
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
M Kwok, A Agathanggelou, N Davies, T Stankovic
Cancers 2021
Neddylation and anti-tumor immunity
X Wang, S Best, AV Danilov
Oncotarget 2021
Targeting the tumor microenvironment in chronic lymphocytic leukemia
R Svanberg, S Janum, PE Patten, AG Ramsay, CU Niemann
Haematologica 2021
Expanded antigen-experienced CD160 + CD8 + effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia
N Bozorgmehr, I Okoye, O Oyegbami, L Xu, A Fontaine, N Cox-Kennett, LM Larratt, M Hnatiuk, A Fagarasanu, J Brandwein, AC Peters, S Elahi
Journal for ImmunoTherapy of Cancer 2021
The Peptide Vaccine of the Future
A Nelde, HG Rammensee, JS Walz
Molecular & cellular proteomics : MCP 2021
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia
JR Rivas, Y Liu, SS Alhakeem, JM Eckenrode, F Marti, JP Collard, Y Zhang, KA Shaaban, N Muthusamy, GC Hildebrandt, RA Fleischman, L Chen, JS Thorson, M Leggas, S Bondada
Leukemia 2021
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
M Jan, AS Sperling, BL Ebert
Nature Reviews Clinical Oncology 2021
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
C Ménard, D Rossille, J Dulong, TT Nguyen, I Papa, M Latour, N Bescher, I Bezier, M Chouteau, T Fest, R Houot, F Morschhauser, K Tarte
Blood Advances 2021
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
L Llaó-Cid, PM Roessner, V Chapaprieta, S Öztürk, T Roider, M Bordas, A Izcue, D Colomer, S Dietrich, S Stilgenbauer, B Hanna, JI Martín-Subero, M Seiffert
Leukemia 2021
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)
JA Whitaker, SA Parikh, TD Shanafelt, NE Kay, RB Kennedy, DE Grill, KM Goergen, TG Call, SS Kendarian, W Ding, GA Poland
Vaccine 2021
Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective
M Kwok, CJ Wu
Frontiers in Oncology 2021
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis
Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Scott Schmid D, Kennedy RB, Weinberg A, Parikh SA
American Journal of Hematology 2021
Long-term Follow-up and Correlative Analysis of two Phase 2 Trials of Rituximab and Lenalidomide followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E
Clinical cancer research 2021
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG
Blood 2021
Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
M Giuliani, A Poggi
Cells 2020
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
Y Kikushige
Journal of Clinical and Experimental Hematopathology 2020
Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL:
T Hofland, I de Weerdt, S Endstra, A Jongejan, L Platenkamp, EB Remmerswaal, PD Moerland, IJ ten Berge, MD Levin, AP Kater, SH Tonino
2020
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells
S Best, , T Liu, N Bruss, A Kittai, OV Danilova, S Murray, A Berger, ND Pennock, EF Lind, AV Danilov
Leukemia 2020
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
PM Roessner, M Seiffert
Leukemia 2020
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
AW Martens, SR Janssen, IA Derks, HC Adams, L Izhak, R van Kampen, SH Tonino, E Eldering, GJ van der Windt, AP Kater
Journal for ImmunoTherapy of Cancer 2020
Human CXCR5 + PD‐1 + CD8 T cells in healthy individuals and patients with hematologic malignancies
T Hofland, AW Martens, JA Bruggen, R Boer, S Schetters, EB Remmerswaal, FJ Bemelman, MD Levin, AD Bins, E Eldering, AP Kater, SH Tonino
European Journal of Immunology 2020
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
V Griggio, F Perutelli, C Salvetti, E Boccellato, M Boccadoro, C Vitale, M Coscia
Frontiers in immunology 2020
Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
S Yi, Y Zhang, W Xiong, W Chen, Z Hou, Y Yang, Y Yan, Y Wei, R Cui, H Wang, Z Yu, H Li, Z Li, W Liu, R Lv, T Wang, K Ru, D Zou, M Shu, L Qiu, D Yu
IBMS BoneKEy 2020
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
S Cadot, C Valle, M Tosolini, F Pont, L Largeaud, C Laurent, JJ Fournie, L Ysebaert, A Quillet-Mary
Biomarker Research 2020
Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome
H Augé, AB Notarantonio, R Morizot, A Quinquenel, LM Fornecker, S Hergalant, P Feugier, J Broséus
Frontiers in immunology 2020
Modeling the Leukemia Microenviroment In Vitro
C Scielzo, P Ghia
Frontiers in Oncology 2020
Mechanisms of resistance to CAR T cell therapies
N Singh, E Orlando, J Xu, J Xu, Z Binder, MK Collins, DM ORourke, JJ Melenhorst
Seminars in Cancer Biology 2020
Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
Z Wang, G Zhou, N Risu, J Fu, Y Zou, J Tang, L Li, H Liu, Q Liu, X Zhu
Cell Transplantation 2020
PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series
I Landego, D Hewitt, I Hibbert, D Dhaliwal, W Pieterse, D Grenier, R Wong, J Johnston, V Banerji
Current Oncology 2020
Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
A Manna, T Kellett, S Aulakh, LJ Lewis-Tuffin, N Dutta, K Knutson, E Chini, J Pinilla-Ibarz, N Lamanna, R Manochakian, F Malavasi, T Sher, AA Chanan-Khan, S Ailawadhi, A Paulus
Blood Advances 2020
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)
TD Shanafelt, NE Kay, SA Parikh, SJ Achenbach, CE Lesnick, CA Hanson, G Kleinstern, JE Olson, AD Norman, KG Rabe, SM Schwager, TG Call, SL Slager
Leukemia 2020
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia
P Banerjee, R Zhang, C Ivan, G Galletti, K Clise-Dwyer, F Barbaglio, L Scarfò, M Aracil, C Klein, W Wierda, W Plunkett, F Caligaris-Cappio, V Gandhi, MJ Keating, MT Bertilaccio
Cancer immunology research 2019
SLAMF6 in health and disease: Implications for therapeutic targeting
B Yigit, N Wang, R Herzog, C Terhorst
Clinical Immunology 2019
Actin Cytoskeleton Straddling the Immunological Synapse between Cytotoxic Lymphocytes and Cancer Cells
H Wurzer, C Hoffmann, AA Absi, C Thomas
Cells 2019
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
Mulder, Wahlin, Österborg, Palma
Cancers 2019
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
I de Weerdt, T Hofland, R de Boer, JA Dobber, J Dubois, D van Nieuwenhuize, M Mobasher, F de Boer, M Hoogendoorn, GA Velders, M van der Klift, EB Remmerswaal, FJ Bemelman, CU Niemann, S Kersting, MD Levin, E Eldering, SH Tonino, AP Kater
Blood Advances 2019
Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
T Hofland, E Eldering, AP Kater, SH Tonino
International journal of molecular sciences 2019
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
JA van Bruggen, AW Martens, JA Fraietta, T Hofland, SH Tonino, E Eldering, MD Levin, PJ Siska, S Endstra, JC Rathmell, CH June, DL Porter, JJ Melenhorst, AP Kater, GJ van der Windt
Blood 2019
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
M Mhibik, A Wiestner, C Sun
International journal of molecular sciences 2019
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling:
T Hofland, S Endstra, CK Gomes, R de Boer, I de Weerdt, V Bobkov, JA Riedl, R Heukers, MJ Smit, E Eldering, MD Levin, AP Kater, SH Tonino
2019
Dissecting CLL through high-dimensional single-cell technologies
SH Gohil, CJ Wu
Blood 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
P Strati, K Takahashi, CB Peterson, MJ Keating, PA Thompson, NG Daver, N Jain, JA Burger, Z Estrov, SM O'Brien, HM Kantarjian, WG Wierda, PA Futreal, A Ferrajoli
Blood Advances 2019
Multiparametric analysis of CD8 + T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy
P Gonnord, M Costa, A Abreu, M Peres, L Ysebaert, S Gadat, S Valitutti
OncoImmunology 2019
Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
H Chiu, P Trisal, C Bjorklund, S Carrancio, EG Toraño, C Guarinos, D Papazoglou, PR Hagner, A BeldiFerchiou, K Tarte, MH DelfauLarue, F Morschhauser, AG Ramsay, AK Gandhi
British Journal of Haematology 2019
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
AM Lesokhin, S Bal, AZ Badros
Cancer immunology research 2019
B-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion
D Asslaber, Y Qi, N Maeding, M Steiner, U Denk, JP Höpner, TN Hartmann, N Zaborsky, R Greil, A Egle
Blood 2019
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army
R García-Muñoz, MJ Nájera, J Feliu, J Antón-Remírez, E Ramalle-Gómara, R Marín-Gorricho, R Peralta, E Gutiérrez-Gamarra, J Nuñez-Rodriguez, R Zafra-Morales, L Aguinaga, MJ Nebot-Villacampa, PM Hernandez-Pérez, G Farfán-Quiroga, C Panizo, E Domínguez-Garrido
Future Science OA 2019
IMiDs New and Old
S Yamshon, J Ruan
Current Hematologic Malignancy Reports 2019
Maintenance therapy for chronic lymphocytic leukaemia
Lee C, Wu Y, Huang T, Lin C, Zou Y, Cheng J, Ho C
The Cochrane Database of Systematic Reviews 2019
PI3K p110δ inactivation antagonizes Chronic Lymphocytic Leukemia and reverses T-cell immune suppression
Shuai Dong, Bonnie K. Harrington, Eileen Hu, Joseph T. Greene, Amy Lehman, Minh H Tran, Ronni Wasmuth, Meixiao Long, Natarajan Muthusamy, Jennifer R. Brown, Amy J Johnson, John C. Byrd
Journal of Clinical Investigation 2018
The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
H Shaim, Z Estrov, D Harris, MH Sanabria, Z Liu, P Ruvolo, PA Thompson, A Ferrajoli, M Daher, J Burger, M Muftuoglu, N Imahashi, L Li, E Liu, AS Alsuliman, R Basar, LN Kerbauy, C Sobieski, E Gokdemir, K Kondo, W Wierda, M Keating, EJ Shpall, K Rezvani
Frontiers in immunology 2018
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
P Kokhaei, M Hojjat-Farsangi, F Mozaffari, A Moshfegh, F Pak, A Rashidy-Pour, M Palma, L Hansson, A Österborg, H Mellstedt, SB Gibson
PloS one 2018
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
HR Robinson, J Qi, EM Cook, C Nichols, EL Dadashian, C Underbayev, SE Herman, NS Saba, K Keyvanfar, C Sun, IE Ahn, S Baskar, C Rader, A Wiestner
Blood 2018
Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity
SS Alhakeem, MK McKenna, KZ Oben, SK Noothi, JR Rivas, GC Hildebrandt, RA Fleischman, VM Rangnekar, N Muthusamy, S Bondada
Journal of immunology (Baltimore, Md. : 1950) 2018
How and when I do allogeneic transplant in CLL
JG Gribben
Blood 2018
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia
G Aue, C Sun, D Liu, JH Park, S Pittaluga, X Tian, E Lee, S Soto, J Valdez, I Maric, M Stetler-Stevenson, C Yuan, Y Nakamura, P Muranski, A Wiestner
Journal of immunology (Baltimore, Md. : 1950) 2018
Signals Controlling Lytic Granule Polarization at the Cytotoxic Immune Synapse
A Kabanova, V Zurli, CT Baldari
Frontiers in immunology 2018
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
C Pleyer, A Wiestner, C Sun
Leukemia & Lymphoma 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
A Egle, M Steurer, T Melchardt, L Weiss, FJ Gassner, N Zaborsky, R Geisberger, K Catakovic, TN Hartmann, L Pleyer, D Voskova, J Thaler, A Lang, M Girschikofsky, A Petzer, R Greil
Annals of Hematology 2018
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
BS Hanna, PM Roessner, H Yazdanparast, D Colomer, E Campo, S Kugler, D Yosifov, S Stilgenbauer, M Schmidt, R Gabriel, P Lichter, M Seiffert
Leukemia 2018
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
C Vitale, A Ferrajoli
Haematologica 2018
Enhanced Activation and Expansion of T Cells Using Mechanically Soft Elastomer Fibers
AP Dang, SD Leo, DR Bogdanowicz, DJ Yuan, SM Fernandes, JR Brown, HH Lu, LC Kam
Advanced Biosystems 2018
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
B Hu, R Jacobs, N Ghosh
Current Hematologic Malignancy Reports 2018
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
BS Hanna, PM Roessner, A Scheffold, BM Jebaraj, Y Demerdash, S Öztürk, P Lichter, S Stilgenbauer, M Seiffert
Leukemia 2018
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation
S Ringelstein-Harlev, I Avivi, M Fanadka, NA Horowitz, T Katz
Cancer Immunology, Immunotherapy 2018
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
K Catakovic, FJ Gassner, C Ratswohl, N Zaborsky, S Rebhandl, M Schubert, M Steiner, JC Gutjahr, L Pleyer, A Egle, TN Hartmann, R Greil, R Geisberger
OncoImmunology 2017
Precancer Atlas to Drive Precision Prevention Trials
A Spira, MB Yurgelun, L Alexandrov, A Rao, R Bejar, K Polyak, M Giannakis, A Shilatifard, OJ Finn, M Dhodapkar, NE Kay, E Braggio, E Vilar, SA Mazzilli, TR Rebbeck, JE Garber, VE Velculescu, ML Disis, DC Wallace, SM Lippman
Cancer research 2017
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
ZY Xu-Monette, M Zhang, J Li, KH Young
Frontiers in immunology 2017
Chronic lymphocytic leukaemia
TJ Kipps, FK Stevenson, CJ Wu, CM Croce, G Packham, WG Wierda, S O'Brien, J Gribben, K Rai
Nature Reviews Disease Primers 2017
Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome
KJ Till, JC Allen, F Talab, K Lin, D Allsup, L Cawkwell, A Bentley, I Ringshausen, AD Duckworth, AR Pettitt, N Kalakonda, JR Slupsky
Scientific Reports 2017
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Q Yin, M Sivina, H Robins, E Yusko, M Vignali, S OBrien, MJ Keating, A Ferrajoli, Z Estrov, N Jain, WG Wierda, JA Burger
Journal of immunology (Baltimore, Md. : 1950) 2017
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia
N Purroy, CJ Wu
Cold Spring Harbor Perspectives in Medicine 2017
Using Murine Models to Investigate Tumor–Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma
TA Herek, CE Cutucache
Frontiers in Oncology 2017
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
K Maharaj, E Sahakian, J Pinilla-Ibarz
Blood Advances 2017
Role of LFA-1 and ICAM-1 in Cancer
M Reina, E Espel
Cancers 2017
Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
PA Thompson, JA Burger
Expert Opinion on Investigational Drugs 2017
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
AD Fesnak, PJ Hanley, BL Levine
Current Hematologic Malignancy Reports 2017
A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy
X Liu, K Rothe, R Yen, C Fruhstorfer, T Maetzig, M Chen, DL Forrest, RK Humphries, X Jiang
Leukemia 2017
Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia
M Villa-Álvarez, S Lorenzo-Herrero, AP Gonzalez-Rodriguez, A López-Soto, AR Payer, E Gonzalez-Garcia, L Huergo-Zapico, S Gonzalez
OncoImmunology 2017
Nurse-like cells promote CLL survival through LFA-3/CD2 interactions
F Boissard, M Tosolini, L Ligat, A Quillet-Mary, F Lopez, JJ Fournié, L Ysebaert, M Poupot
Oncotarget 2017
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
T Jelinek, J Mihalyova, M Kascak, J Duras, R Hajek
Immunology 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
W Ding, BR LaPlant, TG Call, SA Parikh, JF Leis, R He, TD Shanafelt, S Sinha, J Le-Rademacher, AL Feldman, TM Habermann, TE Witzig, GA Wiseman, Y Lin, E Asmus, GS Nowakowski, MJ Conte, DA Bowen, CN Aitken, DL van Dyke, PT Greipp, X Liu, X Wu, H Zhang, CR Secreto, S Tian, E Braggio, LE Wellik, I Micallef, DS Viswanatha, H Yan, AA Chanan-Khan, NE Kay, H Dong, SM Ansell
Blood 2017
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
K Kondo, H Shaim, PA Thompson, JA Burger, M Keating, Z Estrov, D Harris, E Kim, A Ferrajoli, M Daher, R Basar, M Muftuoglu, N Imahashi, A Alsuliman, C Sobieski, E Gokdemir, W Wierda, N Jain, E Liu, EJ Shpall, K Rezvani
Leukemia 2017
Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
MH van Attekum, E Eldering, AP Kater
Haematologica 2017
αII-spectrin in T cells is involved in the regulation of cell-cell contact leading to immunological synapse formation?
JM Meissner, AF Sikorski, T Nawara, J Grzesiak, K Marycz, DM Bogusławska, I Michalczyk, MC Lecomte, B Machnicka, AA Ansari
PloS one 2017
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
S Schliffke, M Sivina, E Kim, L Wenserski, B Thiele, N Akyüz, C Falker-Gieske, D Statovci, A Oberle, T Thenhausen, A Krohn-Grimberghe, C Bokemeyer, N Jain, Z Estrov, A Ferrajoli, W Wierda, M Keating, JA Burger, M Binder
OncoImmunology 2017
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
A Nelde, DJ Kowalewski, L Backert, H Schuster, JO Werner, R Klein, O Kohlbacher, L Kanz, HR Salih, HG Rammensee, S Stevanović, JS Walz
OncoImmunology 2017
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a non-classical Th1-dependent, Bcl-6-deficient process
Piers Patten, Gerardo Ferrer, Shih-Shih Chen, Rita Simone, Sonia Marsilio, Xiao-Jie Yan, Zachary Gitto, Chaohui Yuan, Jonathan Kolitz, Jacqueline Barrientos, Steven Allen, Kanti Rai, Thomas MacCarthy, Charles Chu, Nicholas Chiorazzi
JCI Insight 2016
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells
JA Fraietta, RD Schwab, MV Maus
Seminars in Oncology 2016
Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia
A Mohr, Y Renaudineau, C Bagacean, JO Pers, C Jamin, A Bordron
OncoImmunology 2016
Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements
A Vardi, E Vlachonikola, M Karypidou, E Stalika, V Bikos, K Gemenetzi, C Maramis, A Siorenta, A Anagnostopoulos, S Pospisilova, N Maglaveras, I Chouvarda, K Stamatopoulos, A Hadzidimitriou
Leukemia 2016
Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
J Wu, X Xu, EJ Lee, AY Shull, L Pei, F Awan, X Wang, JH Choi, L Deng, HB Xin, W Zhong, J Liang, Y Miao, Y Wu, L Fan, J Li, W Xu, H Shi
Oncotarget 2016
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
A Bresin, L D'Abundo, MG Narducci, MT Fiorenza, CM Croce, M Negrini, G Russo
Cell Death and Disease 2016
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART before the Horse
SS Kenderian, DL Porter, S Gill
Biology of Blood and Marrow Transplantation 2016
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
M Winqvist, F Mozaffari, M Palma, SE Sylvan, L Hansson, H Mellstedt, A Österborg, J Lundin
Cancer Immunology, Immunotherapy 2016
Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
C Cubillos-Zapata, J Avendaño-Ortiz, R Córdoba, E Hernández-Jiménez, V Toledano, RP de Diego, E López-Collazo
OncoImmunology 2016
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
CE Ryan, B Sahaf, AC Logan, S OBrien, JC Byrd, P Hillmen, JR Brown, MJ Dyer, AR Mato, MJ Keating, S Jaglowski, F Clow, AR Rezvani, L Styles, SE Coutre, DB Miklos
Blood 2016
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
M Palma, G Gentilcore, K Heimersson, F Mozaffari, B Näsman-Glaser, E Young, R Rosenquist, L Hansson, A Österborg, H Mellstedt
Haematologica 2016
'Trained immunity: consequences for lymphoid malignancies
WB Stevens, MG Netea, AP Kater, WJ van der Velden
Haematologica 2016
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells
F Cattaneo, L Patrussi, N Capitani, F Frezzato, MM DElios, L Trentin, G Semenzato, CT Baldari
Oncotarget 2016
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells
N Zaborsky, FJ Gassner, D Asslaber, P Reinthaler, U Denk, S Flenady, JP Hofbauer, B Danner, S Rebhandl, A Harrer, R Geisberger, R Greil, A Egle
Oncotarget 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
C Vitale, L Falchi, E Hacken, H Gao, H Shaim, KV Roosbroeck, G Calin, S O'Brien, S Faderl, X Wang, WG Wierda, K Rezvani, JM Reuben, JA Burger, MJ Keating, A Ferrajoli
Clinical cancer research 2016
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia
M Qorraj, H Bruns, M Böttcher, L Weigand, D Saul, A Mackensen, R Jitschin, D Mougiakakos
Leukemia 2016
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
RL Browning, WH Byrd, N Gupta, J Jones, X Mo, E Hertlein, L Yu, N Muthusamy, JC Byrd
Cancer immunology research 2016
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells
M Pizzi, M Boi, F Bertoni, G Inghirami
Leukemia 2016
Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation
MA Grygorowicz, IS Borycka, E Nowak, E Paszkiewicz-Kozik, G Rymkiewicz, K Błachnio, M Biernacka, M Bujko, J Walewski, S Markowicz
Clinical and Experimental Medicine 2016
B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia
G Galletti, F Caligaris-Cappio, MT Bertilaccio
Leukemia 2016
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting
SH Bachow, N Lamanna
Current Hematologic Malignancy Reports 2016
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
E Hacken, JA Burger
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2015
Haematological malignancies: at the forefront of immunotherapeutic innovation
P Bachireddy, UE Burkhardt, M Rajasagi, CJ Wu
Nature Reviews Cancer 2015
Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions
JE Arnason, JR Brown
Drugs 2015
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors
Maël Heiblig, Mohamed Elhamri, Mauricette Michallet, Xavier Thomas
World journal of stem cells 2015
PD-L1 Checkpoint Blockade Prevents Immune Dysfunction and Leukemia Development in a Mouse Model of Chronic Lymphocytic Leukemia
F McClanahan, B Hanna, S Miller, AJ Clear, P Lichter, JG Gribben, M Seiffert
Blood 2015
Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?
MN Roufaiel, JW Wells, RJ Steptoe
Frontiers in immunology 2015
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E -TCL1 CLL mouse model
F McClanahan, JC Riches, S Miller, WP Day, E Kotsiou, D Neuberg, CM Croce, M Capasso, JG Gribben
Blood 2015
Lymphoma: Immune Evasion Strategies
R Upadhyay, L Hammerich, P Peng, B Brown, M Merad, J Brody
Cancers 2015
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
D Saulep-Easton, FB Vincent, PS Quah, A Wei, SB Ting, CM Croce, C Tam, F Mackay
Leukemia 2015
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
R Maffei, S Fiorcari, S Martinelli, L Potenza, M Luppi, R Marasca
Journal of Hematology & Oncology 2015
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
A Kritharis, M Coyle, J Sharma, AM Evens
Blood 2015
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, SF Lacey, AZ Badros, A Garfall, B Weiss, J Finklestein, I Kulikovskaya, SK Sinha, S Kronsberg, M Gupta, S Bond, L Melchiori, JE Brewer, AD Bennett, AB Gerry, NJ Pumphrey, D Williams, HK Martin, L Ribeiro, T Holdich, S Yanovich, N Hardy, J Yared, N Kerr, S Philip, S Westphal, DL Siegel, BL Levine, BK Jakobsen, M Kalos, CH June
Nature Medicine 2015
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date
K Crassini
World journal of clinical cases 2015
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
P Otáhal, D Průková, V Král, M Fabry, P Vočková, L Latečková, M Trněný, P Klener
OncoImmunology 2015
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)
K Ishii, AJ Barrett
Therapeutic Advances in Hematology 2015
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes
B Sherry, P Jain, PY Chiu, L Leung, SL Allen, JE Kolitz, KR Rai, J Barrientos, S Liang, R Hawtin, N Chiorazzi
Immunologic Research 2015
Initial treatment of CLL: integrating biology and functional status
N Jain, S O'Brien
Blood 2015
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
FJ Gassner, N Zaborsky, K Catakovic, S Rebhandl, M Huemer, A Egle, TN Hartmann, R Greil, R Geisberger
British Journal of Haematology 2015
B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia
N Zaborsky, C Holler, R Geisberger, D Asslaber, FJ Gassner, V Egger, J Pinon-Hofbauer, T Kocher, TN Hartmann, R Greil, A Egle
Haematologica 2015
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo
BS Hanna, F McClanahan, H Yazdanparast, N Zaborsky, V Kalter, PM Rößner, A Benner, C Dürr, A Egle, JG Gribben, P Lichter, M Seiffert
Leukemia 2015
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, KT Marcucci, A Shen, V Gonzalez, D Ambrose, SA Grupp, A Chew, Z Zheng, MC Milone, BL Levine, JJ Melenhorst, CH June
Science Translational Medicine 2015
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses
S Kuramitsu, M Ohno, F Ohka, S Shiina, A Yamamichi, A Kato, K Tanahashi, K Motomura, G Kondo, M Kurimoto, T Senga, T Wakabayashi, A Natsume
Cancer Gene Therapy 2015
Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?
R García-Muñoz, L Llorente
Immunology 2014
The Immunological Synapse
ML Dustin
Cancer immunology research 2014
The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
KA Beckwith, FW Frissora, MR Stefanovski, WH Towns, C Cheney, X Mo, J Deckert, CM Croce, JM Flynn, LA Andritsos, JA Jones, KJ Maddocks, G Lozanski, JC Byrd, N Muthusamy
Leukemia 2014
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
JF Fecteau, LG Corral, EM Ghia, S Gaidarova, D Futalan, IS Bharati, B Cathers, M Schwaederle, B Cui, A Lopez-Girona, D Messmer, TJ Kipps
Blood 2014
Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia
RP Correia, FA Silva, NS Bacal, PV Campregher, N Hamerschlak, GP Amarante-Mendes
Revista Brasileira de Hematologia e Hemoterapia 2014
CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia
W Guo, A Dong, C Xing, X Lin, X Pan, Y Lin, B Zhu, M He, RX Yao
Oncology Letters 2014
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
S Fiorcari, S Martinelli, J Bulgarelli, V Audrito, P Zucchini, E Colaci, L Potenza, F Narni, M Luppi, S Deaglio, R Marasca, R Maffei
Haematologica 2014
Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
A Acebes-Huerta, L Huergo-Zapico, AP Gonzalez-Rodriguez, A Fernandez-Guizan, AR Payer, A López-Soto, S Gonzalez
BioMed Research International 2014
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia
FJ Gassner, N Zaborsky, D Neureiter, M Huemer, T Melchardt, A Egle, S Rebhandl, K Catakovic, TN Hartmann, R Greil, R Geisberger
Haematologica 2014
Lenalidomide, an antiproliferative CLL drug
M Seiffert
Blood 2014
How will B-cell-receptor-targeted therapies change future CLL therapy?
Jeffrey A Jones, John C Byrd
Blood 2014
Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
L Huergo-Zapico, A Acebes-Huerta, AP Gonzalez-Rodriguez, J Contesti, E Gonzalez-García, AR Payer, M Villa-Alvarez, A Fernández-Guizán, A López-Soto, S Gonzalez, SB Gibson
PloS one 2014
Transplantation in Chronic Lymphocytic Leukemia
F McClanahan, J Gribben
Hematology/Oncology Clinics of North America 2014
Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician
JC Byrd, JJ Jones, JA Woyach, AJ Johnson, JM Flynn
Journal of Clinical Oncology 2014
Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium
DF James, L Werner, JR Brown, WG Wierda, JC Barrientos, JE Castro, A Greaves, AJ Johnson, LZ Rassenti, KR Rai, D Neuberg, TJ Kipps
Journal of Clinical Oncology 2014
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
AP Rapoport, NA Aqui, EA Stadtmauer, DT Vogl, YY Xu, M Kalos, L Cai, HB Fang, BM Weiss, A Badros, S Yanovich, G Akpek, P Tsao, A Cross, D Mann, S Philip, N Kerr, A Brennan, Z Zheng, K Ruehle, T Milliron, SE Strome, AM Salazar, BL Levine, CH June
Clinical cancer research 2014
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RA
Oncotarget 2014
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K
Cancer Immunology, Immunotherapy 2014
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation
S Kiaii, AJ Clear, AG Ramsay, D Davies, A Sangaralingam, A Lee, M Calaminici, DS Neuberg, JG Gribben
Journal of Clinical Oncology 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, Y Zhong, JD Hessler, TM Liu, BY Chang, KM Larkin, MR Stefanovski, DL Chappell, FW Frissora, LL Smith, KA Smucker, JM Flynn, JA Jones, LA Andritsos, K Maddocks, AM Lehman, R Furman, J Sharman, A Mishra, MA Caligiuri, AR Satoskar, JJ Buggy, N Muthusamy, AJ Johnson, JC Byrd
Blood 2013
Targeting inflammatory pathways in chronic lymphocytic leukemia
U Rozovski, MJ Keating, Z Estrov
Critical Reviews in Oncology/Hematology 2013
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications
Y Herishanu, BZ Katz, A Lipsky, A Wiestner
Hematology/Oncology Clinics of North America 2013
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia
G Brachtl, JP Hofbauer, R Greil, TN Hartmann
Annals of Hematology 2013
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
AG Ramsay, R Evans, S Kiaii, L Svensson, N Hogg, JG Gribben
Blood 2013
Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia
W Guo, C Xing, A Dong, X Lin, Y Lin, B Zhu, M He, R Yao
Cancer biology & therapy 2013
Lenalidomide and chronic lymphocytic leukemia
AP González-Rodríguez, AR Payer, A Acebes-Huerta, L Huergo-Zapico, M Villa-Alvarez, E Gonzalez-García, S Gonzalez
BioMed Research International 2013
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
D Brusa, S Serra, M Coscia, D Rossi, G D'Arena, L Laurenti, O Jaksic, G Fedele, G Inghirami, G Gaidano, F Malavasi, S Deaglio
Haematologica 2013
Current Topics in Membranes
S Curado, S Kumari, ML Dustin
Current topics in membranes 2013
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
R Wong, C Pepper, P Brennan, D Nagorsen, S Man, C Fegan
Haematologica 2013
Trial Watch: Lenalidomide-based immunochemotherapy
M Semeraro, E Vacchelli, A Eggermont, J Galon, L Zitvogel, G Kroemer, L Galluzzi
OncoImmunology 2013
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism
R Rizzo, V Audrito, P Vacca, D Rossi, D Brusa, M Stignani, D Bortolotti, G D'Arena, M Coscia, L Laurenti, F Forconi, G Gaidano, MC Mingari, L Moretta, F Malavasi, S Deaglio
Haematologica 2013
CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation
Y Nakaima, K Watanabe, T Koyama, O Miura, T Fukuda
PloS one 2013
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
MA Kharfan-Dabaja, WG Wierda, LJ Cooper
Leukemia 2013
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
P Strati, MJ Keating, WG Wierda, XC Badoux, S Calin, JM Reuben, S O'Brien, SM Kornblau, HM Kantarjian, H Gao, A Ferrajoli
Blood 2013
T Cell Ig and Mucin Domain-Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases
KL Clayton, MS Haaland, MB Douglas-Vail, S Mujib, GM Chew, LC Ndhlovu, MA Ostrowski
Journal of immunology (Baltimore, Md. : 1950) 2013
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 CRBN
AK Gandhi, J Kang, CG Havens, T Conklin, Y Ning, L Wu, T Ito, H Ando, MF Waldman, A Thakurta, A Klippel, H Handa, TO Daniel, PH Schafer, R Chopra
British Journal of Haematology 2013
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, R Orlowski, S Kumar, S Usmani, D Roodman, R Niesvizky, H Einsele, KC Anderson, MA Dimopoulos, H Avet-Loiseau, UH Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, L Bergsagel, CS Chim, JJ Lahuerta, J Shah, A Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, WJ Chng, P Moreau, P Sonneveld, H Ludwig, BG Durie, JF Miguel
Leukemia 2013
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
G D'Arena, R Guariglia, FL Rocca, S Trino, V Condelli, LD Martino, VD Feo, P Musto
Clinical and Developmental Immunology 2013
Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
N Shah, B Martin-Antonio, H Yang, S Ku, DA Lee, LJ Cooper, WK Decker, S Li, SN Robinson, T Sekine, S Parmar, J Gribben, M Wang, K Rezvani, E Yvon, A Najjar, J Burks, I Kaur, RE Champlin, CM Bollard, EJ Shpall, E Alici
PloS one 2013
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype
Göthert JR, Eisele L, Klein-Hitpass L, Weber S, Zesewitz ML, Sellmann L, Röth A, Pircher H, Dührsen U, Dürig J
Cancer Immunology, Immunotherapy 2013
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
AG Ramsay, AJ Clear, R Fatah, JG Gribben
Blood 2012
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC
WK Decker, N Shah, D Xing, R Lapushin, S Li, SN Robinson, H Yang, S Parmar, MM Halpert, MJ Keating, JG Gribben, JJ Molldrem, EJ Shpall, WG Wierda
PloS one 2012
Immunological aspects in chronic lymphocytic leukemia (CLL) development
R García-Muñoz, VR Galiacho, L Llorente
Annals of Hematology 2012
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
ES Blix, JM Irish, A Husebekk, J Delabie, L Forfang, AM Tierens, JH Myklebust, A Kolstad
BMC Cancer 2012
Immune Reconstitution in Chronic Lymphocytic Leukemia
JC Riches, AG Ramsay, JG Gribben
Current Hematologic Malignancy Reports 2012
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
JC Riches, JK Davies, F McClanahan, R Fatah, S Iqbal, S Agrawal, AG Ramsay, JG Gribben
Blood 2012
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy
R Weinkove, CR Brooks, JM Carter, IF Hermans, F Ronchese
Haematologica 2012
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
R Martiniani, VD Loreto, CD Sano, A Lombardo, AM Liberati
Advances in Hematology 2012
Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
JM McDaniel, J Pinilla-Ibarz, PK Epling-Burnette
Advances in Hematology 2012
Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
A Cortelezzi, M Sciumè, G Reda
Advances in Hematology 2012
Immunotherapy of acute myeloid leukemia based on γδ T cells
J Gertner-Dardenne, C Fauriat, N Vey, D Olive
OncoImmunology 2012
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A Lopez-Girona, D Mendy, T Ito, K Miller, AK Gandhi, J Kang, S Karasawa, G Carmel, P Jackson, M Abbasian, A Mahmoudi, B Cathers, E Rychak, S Gaidarova, R Chen, PH Schafer, H Handa, TO Daniel, JF Evans, R Chopra
Leukemia Supplements 2012
Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule
JE Castro, J Melo-Cardenas, M Urquiza, JS Barajas-Gamboa, RS Pakbaz, TJ Kipps
Cancer research 2012
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
XC Badoux, MJ Keating, S Wen, WG Wierda, SM O'Brien, S Faderl, R Sargent, JA Burger, A Ferrajoli
Journal of Clinical Oncology 2012
Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia
CI Chen
Current Hematologic Malignancy Reports 2012
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia
Fecteau JF, Kipps TJ
Frontiers in bioscience (Scholar edition) 2012
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
D Bagnara, MS Kaufman, C Calissano, S Marsilio, PE Patten, R Simone, P Chum, XJ Yan, SL Allen, JE Kolitz, S Baskar, C Rader, H Mellstedt, H Rabbani, A Lee, PK Gregersen, KR Rai, N Chiorazzi
Blood 2011
Chronic Lymphocytic Leukemia: An Update on Biology and Treatment
JC Riches, AG Ramsay, JG Gribben
Current Oncology Reports 2011
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines
G Wieërs, N Demotte, D Godelaine, PV der Bruggen
Cancers 2011
The Etiology of Paraneoplastic Autoimmunity
E Maverakis, H Goodarzi, LN Wehrli, Y Ono, MS Garcia
Clinical Reviews in Allergy & Immunology 2011
Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia
JG Gribben, C Hosing, DG Maloney
Biology of Blood and Marrow Transplantation 2011
Immunologic aspects of monoclonal B cell lymphocytosis
MC Lanasa, JB Weinberg
Immunologic Research 2011
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers
JA Dubovsky, D Wang, JJ Powers, E Berchmans, MA Smith, KL Wright, EM Sotomayor, JA Pinilla-Ibarz
Leukemia Research 2011
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation
JM McDaniel, JX Zou, W Fulp, DT Chen, AF List, PK Epling-Burnette
Leukemia 2011
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June
Science Translational Medicine 2011
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
P Pérez-Galán, M Dreyling, A Wiestner
Blood 2011
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach
CS Zent, NE Kay
Leukemia and Lymphoma 2011
Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia
FJ Li, Y Kubagawa, MK McCollum, L Wilson, T Motohashi, LF Bertoli, JC Barton, S Barnes, RS Davis, H Kubagawa
Blood 2011
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
XC Badoux, MJ Keating, S Wen, BN Lee, M Sivina, J Reuben, WG Wierda, SM O'Brien, S Faderl, SM Kornblau, JA Burger, A Ferrajoli
Blood 2011
Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2′-deoxycytidine
JA Dubovsky, JJ Powers, Y Gao, LF Mariusso, EM Sotomayor, JA Pinilla-Ibarz
Leukemia Research 2011
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L, Rossmann E, Widén K, Horváth R, Kokhaei P, Vertuani S, Mellstedt H, Österborg A
Cancer Immunology, Immunotherapy 2011
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells
X Liang, EA Moseman, MA Farrar, V Bachanova, DJ Weisdorf, BR Blazar, W Chen
Blood 2010
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells
RN Damle, C Calissano, N Chiorazzi
Best Practice & Research Clinical Haematology 2010
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia
M Borge, PR Nannini, JG Galletti, PE Morande, JS Avalos, RF Bezares, M Giordano, R Gamberale
Haematologica 2010
The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
M Hudecek, TM Schmitt, S Baskar, MT Lupo-Stanghellini, T Nishida, TN Yamamoto, M Bleakley, CJ Turtle, WC Chang, HA Greisman, B Wood, DG Maloney, MC Jensen, C Rader, SR Riddell
Blood 2010
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
FJ Gassner, L Weiss, R Geisberger, JP Hofbauer, A Egle, TN Hartmann, R Greil, I Tinhofer
Cancer Immunology, Immunotherapy 2010
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine
AE Foster, FV Okur, E Biagi, A Lu, G Dotti, E Yvon, B Savoldo, G Carrum, MA Goodell, HE Heslop, MK Brenner
Leukemia 2010
How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes
W Blum
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2010
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
W Blum, RB Klisovic, H Becker, X Yang, DM Rozewski, MA Phelps, R Garzon, A Walker, JC Chandler, SP Whitman, J Curfman, S Liu, L Schaaf, J Mickle, C Kefauver, SM Devine, MR Grever, G Marcucci, JC Byrd
Journal of Clinical Oncology 2010
Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion
D Xing, AG Ramsay, JG Gribben, WK Decker, JK Burks, M Munsell, S Li, SN Robinson, H Yang, D Steiner, N Shah, JD McMannis, RE Champlin, C Hosing, PA Zweidler-McKay, EJ Shpall, CM Bollard
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia
FT Awan, AJ Johnson, R Lapalombella, W Hu, M Lucas, B Fischer, JC Byrd
Leukemia and Lymphoma 2010
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
CI Chen, PL Bergsagel, H Paul, W Xu, A Lau, N Dave, V Kukreti, E Wei, C Leung-Hagesteijn, ZH Li, J Brandwein, M Pantoja, J Johnston, S Gibson, T Hernandez, D Spaner, S Trudel
Journal of Clinical Oncology 2010
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
JA Burger, P Ghia, A Rosenwald, F Caligaris-Cappio
Blood 2009
Adoptive T-cell therapy for B-cell malignancies
M Hudecek, LD Anderson, T Nishida, SR Riddell
Expert Review of Hematology 2009
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia
T Nishida, M Hudecek, A Kostic, M Bleakley, EH Warren, D Maloney, R Storb, SR Riddell
Clinical cancer research 2009
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
L Pleyer, A Egle, TN Hartmann, R Greil
Nature Reviews Clinical Oncology 2009
From pathogenesis to treatment of chronic lymphocytic leukaemia
T Zenz, D Mertens, R Küppers, H Döhner, S Stilgenbauer
Nature Reviews Cancer 2009
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
RL Dieu, DC Taussig, AG Ramsay, R Mitter, F Miraki-Moud, R Fatah, AM Lee, TA Lister, JG Gribben
Blood 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
R Lapalombella, L Andritsos, Q Liu, SE May, R Browning, LV Pham, KA Blum, W Blum, A Ramanunni, CA Raymond, LL Smith, A Lehman, X Mo, D Jarjoura, CS Chen, R Ford, C Rader, N Muthusamy, AJ Johnson, JC Byrd
Blood 2009
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug
AG Ramsay, JG Gribben
Haematologica 2009
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
G Gorgun, AG Ramsay, TA Holderried, D Zahrieh, RL Dieu, F Liu, J Quackenbush, CM Croce, JG Gribben
Proceedings of the National Academy of Sciences 2009
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
AG Ramsay, AJ Clear, G Kelly, R Fatah, J Matthews, F Macdougall, TA Lister, AM Lee, M Calaminici, JG Gribben
Blood 2009
Mechanism of action of lenalidomide in hematological malignancies
V Kotla, S Goel, S Nischal, C Heuck, K Vivek, B Das, A Verma
Journal of Hematology & Oncology 2009
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
G Aue, N Njuguna, X Tian, S Soto, T Hughes, B Vire, K Keyvanfar, F Gibellini, J Valdez, C Boss, L Samsel, JP McCoy, WH Wilson, S Pittaluga, A Wiestner
Haematologica 2009
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
NE Kay, TD Shanafelt, TG Call, W Wu, BR Laplant
Leukemia and Lymphoma 2009
Chronic lymphocytic leukemia: Treatment options for patients with refractory disease
M Motta, WG Wierda, A Ferrajoli
Cancer 2009
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
R Lapalombella, B Yu, G Triantafillou, Q Liu, JP Butchar, G Lozanski, A Ramanunni, LL Smith, W Blum, L Andritsos, DS Wang, A Lehman, CS Chen, AJ Johnson, G Marcucci, RJ Lee, LJ Lee, S Tridandapani, N Muthusamy, JC Byrd
Blood 2008
Chronic Lymphocytic Leukemia
N Chiorazzi, KR Rai, M Ferrarini
New England Journal of Medicine 2005

← Previous 1 2 … 11 12 13 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts